These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

324 related items for PubMed ID: 26231305

  • 1. Baseline Predictors of 12-Month Treatment Response to Ranibizumab in Patients With Wet Age-Related Macular Degeneration.
    Regillo CD, Busbee BG, Ho AC, Ding B, Haskova Z.
    Am J Ophthalmol; 2015 Nov; 160(5):1014-1023.e2. PubMed ID: 26231305
    [Abstract] [Full Text] [Related]

  • 2. Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration.
    Ho AC, Busbee BG, Regillo CD, Wieland MR, Van Everen SA, Li Z, Rubio RG, Lai P, HARBOR Study Group.
    Ophthalmology; 2014 Nov; 121(11):2181-92. PubMed ID: 25015215
    [Abstract] [Full Text] [Related]

  • 3. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration.
    Busbee BG, Ho AC, Brown DM, Heier JS, Suñer IJ, Li Z, Rubio RG, Lai P, HARBOR Study Group.
    Ophthalmology; 2013 May; 120(5):1046-56. PubMed ID: 23352196
    [Abstract] [Full Text] [Related]

  • 4. Morphologic parameters relevant for visual outcome during anti-angiogenic therapy of neovascular age-related macular degeneration.
    Simader C, Ritter M, Bolz M, Deák GG, Mayr-Sponer U, Golbaz I, Kundi M, Schmidt-Erfurth UM.
    Ophthalmology; 2014 Jun; 121(6):1237-45. PubMed ID: 24684838
    [Abstract] [Full Text] [Related]

  • 5. Ranibizumab Treatment for Pigment Epithelial Detachment Secondary to Neovascular Age-Related Macular Degeneration: Post Hoc Analysis of the HARBOR Study.
    Sarraf D, London NJ, Khurana RN, Dugel PU, Gune S, Hill L, Tuomi L.
    Ophthalmology; 2016 Oct; 123(10):2213-24. PubMed ID: 27566855
    [Abstract] [Full Text] [Related]

  • 6. Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point.
    Brown DM, Chen E, Mariani A, Major JC, SAVE Study Group.
    Ophthalmology; 2013 Feb; 120(2):349-54. PubMed ID: 23131717
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Predictive Value of Retinal Morphology for Visual Acuity Outcomes of Different Ranibizumab Treatment Regimens for Neovascular AMD.
    Waldstein SM, Wright J, Warburton J, Margaron P, Simader C, Schmidt-Erfurth U.
    Ophthalmology; 2016 Jan; 123(1):60-9. PubMed ID: 26481821
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of the siRNA PF-04523655 versus ranibizumab for the treatment of neovascular age-related macular degeneration (MONET Study).
    Nguyen QD, Schachar RA, Nduaka CI, Sperling M, Klamerus KJ, Chi-Burris K, Yan E, Paggiarino DA, Rosenblatt I, Aitchison R, Erlich SS, MONET Clinical Study Group.
    Ophthalmology; 2012 Sep; 119(9):1867-73. PubMed ID: 22683252
    [Abstract] [Full Text] [Related]

  • 10. Tolerating Subretinal Fluid in Neovascular Age-Related Macular Degeneration Treated with Ranibizumab Using a Treat-and-Extend Regimen: FLUID Study 24-Month Results.
    Guymer RH, Markey CM, McAllister IL, Gillies MC, Hunyor AP, Arnold JJ, FLUID Investigators.
    Ophthalmology; 2019 May; 126(5):723-734. PubMed ID: 30502372
    [Abstract] [Full Text] [Related]

  • 11. Subfoveal choroidal thickness as a potential predictor of visual outcome and treatment response after intravitreal ranibizumab injections for typical exudative age-related macular degeneration.
    Kang HM, Kwon HJ, Yi JH, Lee CS, Lee SC.
    Am J Ophthalmol; 2014 May; 157(5):1013-21. PubMed ID: 24487050
    [Abstract] [Full Text] [Related]

  • 12. Macular Atrophy in the HARBOR Study for Neovascular Age-Related Macular Degeneration.
    Sadda SR, Tuomi LL, Ding B, Fung AE, Hopkins JJ.
    Ophthalmology; 2018 Jun; 125(6):878-886. PubMed ID: 29477692
    [Abstract] [Full Text] [Related]

  • 13. Correlation of 3-Dimensionally Quantified Intraretinal and Subretinal Fluid With Visual Acuity in Neovascular Age-Related Macular Degeneration.
    Waldstein SM, Philip AM, Leitner R, Simader C, Langs G, Gerendas BS, Schmidt-Erfurth U.
    JAMA Ophthalmol; 2016 Feb; 134(2):182-90. PubMed ID: 26661463
    [Abstract] [Full Text] [Related]

  • 14. Predictors of 1-year visual outcome in neovascular age-related macular degeneration following intravitreal ranibizumab treatment.
    Bloch SB, la Cour M, Sander B, Hansen LK, Fuchs J, Lund-Andersen H, Larsen M.
    Acta Ophthalmol; 2013 Feb; 91(1):42-7. PubMed ID: 22008284
    [Abstract] [Full Text] [Related]

  • 15. Five-year treatment outcomes following intravitreal ranibizumab injections for neovascular age-related macular degeneration in Japanese patients.
    Wada I, Oshima Y, Shiose S, Kano K, Nakao S, Kaizu Y, Yoshida S, Ishibashi T, Sonoda KH.
    Graefes Arch Clin Exp Ophthalmol; 2019 Jul; 257(7):1411-1418. PubMed ID: 31119425
    [Abstract] [Full Text] [Related]

  • 16. Treat and Extend versus Pro Re Nata regimens of ranibizumab in neovascular age-related macular degeneration: a comparative 12 Month study.
    Hatz K, Prünte C.
    Acta Ophthalmol; 2017 Feb; 95(1):e67-e72. PubMed ID: 27009503
    [Abstract] [Full Text] [Related]

  • 17. 24-month clinical outcomes of a treat-and-extend regimen with ranibizumab for wet age-related macular degeneration in a real life setting.
    Vardarinos A, Gupta N, Janjua R, Iron A, Empeslidis T, Tsaousis KT.
    BMC Ophthalmol; 2017 Apr 27; 17(1):58. PubMed ID: 28449645
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial.
    Kodjikian L, Souied EH, Mimoun G, Mauget-Faÿsse M, Behar-Cohen F, Decullier E, Huot L, Aulagner G, GEFAL Study Group.
    Ophthalmology; 2013 Nov 27; 120(11):2300-9. PubMed ID: 23916488
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.